DNAPrint genomics, Inc. Welcomes Ramin Mirhashemi, M.D.
Business Editors
DALLAS & CALGARY, Alberta--(BUSINESS WIRE)--Sept. 28, 2000--
DNAPrint genomics, Inc. (Pink Sheets:DNAP), a Sarasota, Florida-based
genomics company, announced today that it has added Ramin Mirhashemi,
M.D. to its Scientific Advisory Board.
Dr. Mirhashemi, currently serves as Director of the University of
Miami/JMH/Sylvester Cancer Center and Familial Ovarian/Breast Cancer
Center, in Miami, Florida. He is an assistant Professor, Department of
Obstetrics and Gynecology and a Clinical Fellow in Gynecologic
Oncology at the University of Miami School of Medicine. Dr. Mirhashemi
is the recipient of the prestigious ACOG/Ortho-McNeil Fellowship
Grant, and has accumulated 8 different honors and awards as a
Gynecologic Oncologist and Surgeon.
CEO/CSO Dr. Tony Frudakis said, "Dr. Mirhashemi is an extremely
valuable addition to our Scientific Advisory Board. His experience and
expertise with biopharmaceutical partners and experimental/clinical
trial study design will help guide the structure and placement of our
cancer pharmacogenomics studies."
About DNAPrint genomics
DNAPrint genomics, Inc. is developing complex genetic analytics
and knowledge resources for next generations personalized medicine.
The company provides practitioners of genomic research and
personalized medicine with a comprehensive system for complex trait
dissection and patient classification. DNAPrint genomics, Inc. was
founded by a group of scientists with research and commercial
experience in high-level mathematical modeling, programming and
molecular genetics. For more information about the company, please
visit www.stocktribe.com
Except for factual statements made herein, the information
contained in this press release consists of forward-looking statements
that involve risks and uncertainties. The Company's actual results
could differ materially from those contained in such statements.
Factors that could cause or contribute to such differences include
unexpected shortages of critical components, rescheduling or
cancellation of customer orders, the timing and market acceptance of
new product introductions by the Company and its competitors, and
general competition and price pressures in the marketplace.
Stocktribe.com has not been compensated for this summary, nor do
we hold a position in this company.
--30--jlm/in*
CONTACT: DNAPrint genomics, Inc.
Craig Hall, 941/923-1949
or
Stocktribe.com
Mike Hale, 403/228-3685
Website: www.stocktribe.com
KEYWORD: TEXAS INTERNATIONAL CANADA
INDUSTRY KEYWORD: PHARMACEUTICAL MEDICAL MANAGEMENT CHANGES
Today's News On The Net - Business Wire's full file on the Internet
with Hyperlinks to your home page.
URL: businesswire.com
*** end of story *** |
